Abstract
Dementia, which can be induced by diverse factors, is a clinical syndrome characterized by the decline of cognitive function. Behavioral and psychological symptoms of dementia (BPSD) include depression, agitation, and aggression. Dementia causes a heavy burden on patients and their caregivers. Patients with BPSD should be assessed comprehensively by practitioners and offered appropriate non-pharmacologic and pharmacologic therapy. Nonpharmacologic therapy has been recommended as the basal treatment for BPSD; however, pharmacologic therapy is required under many situations. Medications, including antipsychotic agents, antidepressants, sedative and hypnotic agents, mood stabilizers, cholinesterase inhibitors, and amantadine, are extensively used in clinical practice. We have reviewed the progression of pharmacologic therapy for BPSD.
Keywords: Alzheimer’s disease, antipsychotic, behavioral and psychological symptoms of dementia, dementia, drug, psychiatric symptoms.
Current Neuropharmacology
Title:Drug Therapy for Behavioral and Psychological Symptoms of Dementia
Volume: 14 Issue: 4
Author(s): Feng Wang, Ting-Yi Feng, Shilin Yang, Maurice Preter, Jiang-Ning Zhou and Xiao-Ping Wang
Affiliation:
Keywords: Alzheimer’s disease, antipsychotic, behavioral and psychological symptoms of dementia, dementia, drug, psychiatric symptoms.
Abstract: Dementia, which can be induced by diverse factors, is a clinical syndrome characterized by the decline of cognitive function. Behavioral and psychological symptoms of dementia (BPSD) include depression, agitation, and aggression. Dementia causes a heavy burden on patients and their caregivers. Patients with BPSD should be assessed comprehensively by practitioners and offered appropriate non-pharmacologic and pharmacologic therapy. Nonpharmacologic therapy has been recommended as the basal treatment for BPSD; however, pharmacologic therapy is required under many situations. Medications, including antipsychotic agents, antidepressants, sedative and hypnotic agents, mood stabilizers, cholinesterase inhibitors, and amantadine, are extensively used in clinical practice. We have reviewed the progression of pharmacologic therapy for BPSD.
Export Options
About this article
Cite this article as:
Wang Feng, Feng Ting-Yi, Yang Shilin, Preter Maurice, Zhou Jiang-Ning and Wang Xiao-Ping, Drug Therapy for Behavioral and Psychological Symptoms of Dementia, Current Neuropharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570159X14666151208114232
DOI https://dx.doi.org/10.2174/1570159X14666151208114232 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Risk Factors for Depression in Alzheimer´s Disease Patients
Current Alzheimer Research Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Mild Systemic Inflammation has a Neuroprotective Effect After Stroke in Rats
Current Neurovascular Research Plant Polyphenols as Neuroprotective Agents in Parkinson’s Disease Targeting Oxidative Stress
Current Drug Targets Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Clearance of Beta-Amyloid in the Brain
Current Medicinal Chemistry Meta-Analysis of the Effectiveness and Safety of Prophylactic Use of Nimodipine in Patients with an Aneurysmal Subarachnoid Haemorrhage
CNS & Neurological Disorders - Drug Targets Natural Products as Sources of New Lead Compounds for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry QSAR Modeling of Histamine H3R Antagonists/inverse Agonists as Future Drugs for Neurodegenerative Diseases
Current Neuropharmacology Cerebrovascular Changes and Neurodegeneration Related to Hyperlipidemia: Characteristics of the Human ApoB-100 Transgenic Mice
Current Pharmaceutical Design Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Relationship of Neurofilament Light (NfL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia
Current Alzheimer Research When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy
Current Pharmaceutical Design Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Drugs and Aggression
Recent Patents on CNS Drug Discovery (Discontinued) The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design Recent Approaches to Novel Anti-Alzheimer Therapy
Current Pharmaceutical Design Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale – Cognitive Subscale (ADASCog)
Current Alzheimer Research Antipsychotic Drugs and Cerebrovascular Events in Elderly Patients with Dementia: A Systematic Review
Mini-Reviews in Medicinal Chemistry Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery